search

Active clinical trials for "Hepatitis C, Chronic"

Results 651-660 of 1088

Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR...

Hepatitis CChronic

This is a Phase IV, open-label, multi-center study to evaluate the real world sustained virological response rate, subject adherence, and subject reported outcomes during and after treatment of non-cirrhotic genotype 1 chronic hepatitis C subjects aged 18 years and older, with VIEKIRA PAK (ombitasvir, paritaprevir/r, dasabuvir), with or without RBV (ribavirin).

Completed20 enrollment criteria

ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced,...

Hepatitis C Virus (HCV)

This is a study to evaluate ABT 450/r/ABT-267 and ABT-333 in treatment-naïve and treatment-experienced Asian adults with subgenotype 1b chronic HCV without cirrhosis.

Completed12 enrollment criteria

DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)

Chronic Hepatitis C InfectionHBV Coinfection1 more

This is a prospective study to determine the incidence, morbidity, mortality and predisposing factors for the reactivation of hepatitis B virus replication during direct anti-HCV treatment of HCV/HBV co-infection patients.

Completed8 enrollment criteria

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

Hepatic FailureHepatic Impairment1 more

The objective was to determine if hepatitis C virus (HCV) infection or mild to severe hepatic impairment (Child-Pugh Classes A, B, and C) altered the PK of buprenorphine, norbuprenorphine, or naloxone.

Completed24 enrollment criteria

Hepatitis C Virus(HCV) Heart and Lung Study

Hepatitis CChronic5 more

This is a multicenter study in Hepatitis C Virus (HCV) infected adult patients who also have advanced cardiac disease or advanced lung disease.

Completed38 enrollment criteria

A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype...

Hepatitis CChronic

This multi-center study will evaluate the viral response in patients with chronic hepatitis C, genotype 1, 2, 3 & 4 on standard anti-viral treatment with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin). Patients will receive weekly subcutaneous Pegasys plus daily oral Copegus for 24 weeks (genotype 2 & 3) or 48 weeks (genotype 1 & 4). Patients identified as slow responders/non-rapid virological responders will be eligible for an additional 24 weeks of treatment.

Completed14 enrollment criteria

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females...

Chronic Hepatitis C

The purpose of this study is to demonstrate the relative bioavailability of Ribavirin 200 capsules and Rebetol 200 mg capsules in females under non-fasting conditions.

Completed3 enrollment criteria

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females...

Chronic Hepatitis C

The purpose of this study is to demonstrate the relative bioavailability of Ribavirin 200 capsules and Rebetol 200 mg capsules in females under fasting conditions.

Completed3 enrollment criteria

Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

Chronic Hepatitis C

This study is being conducted to see if the investigational medication, valopicitabine, is safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis C infection.

Completed6 enrollment criteria

Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination

Chronic Hepatitis cMetabolic Syndrome

The purpose of the study is to determine if statin can affect the clinical outcome of chronic hepatitis C patients receiving Sofosbuvir/Daclatasvir/Ribavirin combination

Completed17 enrollment criteria
1...656667...109

Need Help? Contact our team!


We'll reach out to this number within 24 hrs